"Researchers at the National Eye Institute (NEI) have found a unique cell type that, in tests on mice, can protect against uveitis—a group of inflammatory diseases that affect the eye and can cause vision loss.
Uveitis occurs when "...
DOSAGE AND ADMINISTRATION
One drop of PROLENSA ophthalmic solution should be applied to the affected eye once daily beginning 1 day prior to cataract surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.
Use with Other Topical Ophthalmic Medications
PROLENSA ophthalmic solution may be administered in conjunction with other topical ophthalmic medications such as alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, and mydriatics. Drops should be administered at least 5 minutes apart.
Dosage Forms And Strengths
Topical ophthalmic solution: bromfenac 0.07%
Storage And Handling
PROLENSA (bromfenac ophthalmic solution) 0.07% is supplied in a white LDPE plastic squeeze bottle with a 15 mm LDPE white dropper-tip and 15 mm polypropylene gray cap as follows:
1.6 mL in a 7.5 mL container (NDC 24208-602-01)
3 mL in a 7.5 mL container (NDC 24208-602-03)
Store at 15° – 25°C (59° – 77°F).
Manufactured by: Bausch & Lomb Incorporated, Tampa, FL 33637. Revised: 4/2013This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 4/15/2013
Additional Prolensa Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.